Although the precise molecular details of this interaction in vivo remain unclear, selective inhibition of TTG in the small intestine might represent a therapeutically useful strategy for countering the immunotoxic response to dietary gluten in CD. This evidence concerns the gene TGM2 and Cowden disease.